Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 61, Issue 2, Pages 815-824Publisher
IOS PRESS
DOI: 10.3233/JAD-161198
Keywords
Alzheimer's disease; clinical trial; hypertension; parental history; renin angiotensin system; vascular risk
Categories
Funding
- National Institute on Aging [K01AG042498, 1RF1AG051514-01]
- Emory Alzheimer's Disease Research Center [NIH-NIA 5 P50 AG025688]
- MRC [MC_PC_13088] Funding Source: UKRI
- Medical Research Council [MC_PC_13088] Funding Source: researchfish
- NATIONAL INSTITUTE ON AGING [K01AG042498] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Research indicates that certain antihypertensive medications alter Alzheimer's disease (AD) biomarkers in Caucasians. The renin angiotensin system (RAS) regulates blood pressure (BP) in the body and the brain and may directly influence AD biomarkers, including amyloid-beta (A beta) neuropathology, cerebral blood flow (CBF), and inflammatory markers. This hypothesis is supported by studies, including ours, showing that antihypertensives targeting the RAS reduce the risk and slow the progression of AD in Caucasians. While mounting evidence supports a protective role of RAS medications in Caucasians, this mechanism has not been explored in African Americans. To assess the mechanism by which RAS medications modify the brain RAS, cerebrospinal fluid (CSF) A beta, CBF, and inflammatory markers in African Americans, we are conducting an eight month, Phase Ib randomized, placebo controlled trial, enrolling 60 middle-aged (45-70 years), non-demented individuals, at risk for AD by virtue of a parental history. Participants include normotensive and treated hypertensives that have never been exposed to a RAS medication. Participants are randomized (1 : 1: 1) by gender and BP medication use (yes/no) to one of three groups: placebo, or 20 mg, or 40 mg telmisartan (Micardis), to determine the dose required to penetrate the CNS. Our overarching hypothesis is that, compared to placebo, both doses of telmisartan will penetrate the CNS and produce salutary, dose dependent effects on the brain RAS as well as CSF A beta, CBF, and CSF inflammatory markers in African Americans, over eight months. This manuscript describes the trial rationale and design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available